公开(公告)号：EP2809346A1

公开(公告)日：2014-12-10

申请号：EP13703506.9

申请日：2013-02-01

申请人： GenVec, Inc.

发明人： BRUDER, Joseph T. ,  GALL, Jason G., D. ,  MCVEY, Duncan ,  BROUGH, Douglas E.

IPC分类号： A61K39/015 ,  C12N7/00 ,  C12N15/861

CPC分类号： A61K39/015 ,  A61K2039/5256 ,  A61K2039/53 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10043 ,  C12N2710/10321 ,  C12N2710/10322 ,  C12N2710/10343 ,  Y02A50/412

摘要： The invention provides an adenovirus or adenoviral vector characterized by comprising a nucleic acid sequence encoding one or more Plasmodium antigens and one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein, as well as a method of inducing an immune response against Plasmodium falciparum in a mammal by administering the adenovirus or adenoviral vector to the mammal.

公开(公告)号：EP1649028B1

公开(公告)日：2012-08-22

申请号：EP04779179.3

申请日：2004-07-26

申请人： GENVEC, INC. ,  The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services

发明人： GALL, Jason G., D. ,  WICKHAM, Thomas, J. ,  ENRIGHT, William, J. ,  BROUGH, Douglas, E. ,  ZUBER, Mohammed ,  KING, C., Richter ,  NABEL, Gary J. ,  CHENG, Cheng

IPC分类号： C12N15/861 ,  A61K39/235

CPC分类号： C12N15/86 ,  A61K48/00 ,  A61K2039/5256 ,  C07K2319/00 ,  C12N2710/10343 ,  C12N2710/10345

摘要： The invention provides a method of inducing an immune response in a mammal. The method comprises administering to the mammal a non-subgroup C adenoviral vector comprising an adenoviral fiber protein having an amino acid sequence comprising about 80 % or more identity to an amino acid sequence encoding a subgroup C adenoviral fiber protein. The adenoviral vector further comprises a nucleic acid sequence encoding an antigen which is expressed in the mammal to induce an immune response. The invention further comprises a method of producing an adenoviral vector, and a composition comprising a serotype 41 or a serotype 35 adenoviral vector and a carrier. The invention also provides an adenoviral vector comprising a nucleic acid sequence encoding an adenoviral pIX protein operably linked to a heterologous expression control sequence, as well as a method of enhancing the stability and/or packaging capacity of an adenoviral vector.